Cefdinir: profile and news

(PZ) Medicis Announces FDA Approval of Broader Indication for ...  Mar 2, 2006
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Houston Chronicle,

Strep throat grows stronger  Feb 3, 2006
...antibiotics such as cephalexin, and only 7 percent of children receiving newer generation cephalosporins, such as cefpodoxime and cefdinir, return to the doctor ... - Quad City Times,

Medicis to Present at Merrill Lynch 17th Annual Global ...  Feb 3, 2006
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Genetic Engineering News,

Strep throat grows stronger  Feb 3, 2006
...antibiotics such as cephalexin, and only 7 percent of children receiving newer generation cephalosporins, such as cefpodoxime and cefdinir, return to the doctor ... - Quad City Times,

An open letter to the pharmaceutical industry  Jan 29, 2006
But now nobody makes it, so we usually use cefdinir for those patients.It works just as well, but since it is new and fancy, costs more than cefixime. ... - Staunton News Leader,

Abbott shares rise on Q4 and Guidant win  Jan 26, 2006
...during the period was also supported by: the cholesterol-buster TriCor (fenofibrate), up 37.5% to $312 million; the antibiotic Omnicef (cefdinir), rising 27.5 ... - Pharma Times (subscription),

Kids tee off  Jan 10, 2006
...antibiotics such as cephalexin, and only 7 percent of children receiving newer-generation cephalosporins, such as cefpodoxime and cefdinir, return to the doctor ... - Indianapolis Star,

Medicis Board Unanimously Rejects Mentor Proposal  Nov 20, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Business Wire (press release),

Astellas Filed Lawsuit against Taiyo Yakuhin Co., Ltd. for ...  Sep 15, 2005
...(“Taiyo�; headquarters: Nagoya) demanding that Taiyo stop infringing Astellas’ patent rights on its oral cephalosporin antibiotic cefdinir (brand name ... - PharmaLive.com (press release),

Medicis to Present at UBS Global Life Sciences Conference  Sep 26, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - PharmaLive.com (press release),

Medicis to Present at Thomas Weisel Partners Healthcare Tailwinds ...  Sep 6, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Business Wire (press release),

Medicis to Present at Banc of America Securities 2005 Specialty ...  Jul 25, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Business Wire (press release) <**results**>

Medicis to Present at Thomas Weisel Partners Growth Forum 7.0  Jun 9, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - PharmaLive.com (press release),

Medicis Declares Cash Dividend  Jun 15, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Business Wire (press release),

Medicis Reports Third Quarter Fiscal 2005 Financial Results  Apr 21, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - PharmaLive.com,

Medicis Announces FDA Approval of AMMONUL for Urea Cycle Disorder  Feb 18, 2005
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R ... - Business Wire (press release),

Antacids (aluminum- or magnesium-containing)

Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox^® TC suspension reduces the rate (C_max) and extent (AUC) of absorption by approximately 40%. Time to reach C_max is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.

Probenecid

As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.

Iron Supplements and Foods Fortified With Iron

Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO₄) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.

The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.

Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.

There have been rare reports of reddish stools in patients who have received cefdinir in Japan. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.

Drug/Laboratory Test Interactions

A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest^®, Benedictís solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix^® or Tes-Tape^®) be used. Cephalosporins are known to occasionally induce a positive direct Coombsí test.